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Abstract
 
Elucidation of pathways involved in mouse strain–dependent variation in the hematopoietic
stem cell (HSC) compartment may reveal novel mechanisms relevant in vivo. Here, we dem-
 
onstrate genetically determined variation in the proliferation of lin
 
 
 
Sca1
 
  
 
kit
 
 
 
 (LSK) primitive
hematopoietic progenitor cells in response to transforming growth factor-
 
  
 
(TGF-
 
 
 
) 2, the
dose response of which was biphasic with a stimulatory effect at low concentrations. In contrast,
 
the dose responses of TGF-
 
 
 
1 or -
 
 
 
3 were inhibitory and did not show mouse strain–dependent
variation. A quantitative trait locus (QTL) for the effect of TGF-
 
 
 
2 was identified on chromo-
some 4 overlapping with a QTL regulating the frequency of LSK cells. These overlapping
QTL were corroborated by the observation that the frequency of LSK cells is lower in adult
 
Tgfb2
 
   
 
 mice than in wild-type littermates, indicating that TGF-
 
 
 
2 is a genetically deter-
mined positive regulator LSK number in vivo. Furthermore, adult 
 
Tgfb2
 
   
 
 mice have a defect
in competitive repopulation potential that becomes more pronounced upon serial transplantation.
In fetal TGF-
 
 
 
2–deficient HSCs, a defect only appears after serial reconstitution. These data
suggest that TGF-
 
 
 
2 can act cell autonomously and is important for HSCs that have under-
gone replicative stress. Thus, TGF-
 
 
 
2 is a novel, genetically determined positive regulator of
adult HSCs.
Key words: growth inhibitors • immunologic and biologic factors • hematopoiesis • autocrine 
communication • growth and embryonic development
 
Introduction
 
The lifelong production of blood cells is maintained by
hematopoietic stem cells (HSCs) that display the capacity
to differentiate into multiple lineages of mature cells and to
self-renew. Although these characteristics of stem cells have
been established for some time, the underlying regulatory
mechanisms remain poorly understood (1, 2). The observation
that HSC number and function vary in inbred stains of
mice provides strong evidence that these mechanisms are,
in part, genetically determined (3–11). A powerful approach
to begin to dissect the regulation of HSCs is the investigation
of genetically determined variation in the function and size
of the HSC compartment by quantitative trait analysis. We
have demonstrated previously genetic variation in the
number and frequency of hematopoietic stem and progenitor
cells as determined by the lin
 
 
 
Sca1
 
  
 
kit
 
 
 
 (LSK) phenotype
and in their response to the early acting cytokines kit ligand
(KL), flt3 ligand (flt3L), and thrombopoietin (TPO). Linkage
analysis identified quantitative trait loci on chromosomes 2,
4, and 7 for the frequency of LSK cells, and on chromo-
some 2 and X for their response to early acting cytokines
(9). The observation that differential responsiveness to
these critical positive regulators of HSCs (12, 13) may be
involved in the genetic variation in the HSC compartment
raised the question whether there is also genetic variation
in the responsiveness to negative regulators. One of the
 
most potent negative regulators of hematopoiesis is TGF-
 
 
 
1
(14, 15), which inhibits the proliferative response of hemato-
poietic progenitors to early acting cytokines (16–18). TGF-
 
 
 
1
is expressed in primitive hematopoietic progenitor and stem
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TGF-
 
 
 
2 Regulation of HSC
 
6
 
cells. Inhibition of TGF-
 
 
 
1 activity by antibodies or anti-
sense oligonucleotides enhanced the proliferation of these
cells in vitro (15), and increased the repopulating capacity
of HSCs in vivo (19), suggesting a negative regulatory
role that is, in part, cell autonomous. Both mice and hu-
mans express two other TGF-
 
 
 
 isoforms, TGF-
 
 
 
2 and
TGF-
 
 
 
3, that share significant sequence homology with
and signal through the same receptor complex as TGF-
 
 
 
1
(20, 21). Although some in vitro analyses have described a
potent inhibitory effect for TGF-
 
 
 
3 (22), and a weaker
inhibitory effect for TGF-
 
 
 
2 (14, 23) on early hemato-
poietic progenitor cells, their role in hematopoietic regu-
lation remains largely unknown. The role of the individ-
ual TGF-
 
 
 
 isoforms in adult hematopoiesis in vivo is
unclear as homozygous deletion of each is lethal at or
shortly after birth (20).
The goal of the studies reported here was to determine
whether there is genetically determined variation in the re-
sponsiveness of hematopoietic stem and progenitor cells to
TGF-
 
 
 
 in inbred mice, and, if so, how this genetic variation
would impact the regulation of the hematopoietic stem and
progenitor cell compartment in vivo. We show here that
TGF-
 
 
 
2 is, in fact, a positive regulator of HSCs in vivo, and
is likely involved in genetically determined variation in the
function and size of the HSC compartment.
 
Materials and Methods
 
Mice.
 
8-wk-old C57BL/6J, DBA/2J, BALB/cJ, BXD re-
combinant inbred (RI), and tgfb2
 
tm1doe
 
 mice were purchased from
Jackson Laboratories. C57BL/6.SJL-
 
Ptprca
 
Pep3b/BoyJ
 
 mice were pur-
chased from the National Cancer Institute. Experiments and ani-
mal care were performed in accordance with the Mount Sinai In-
stitutional Animal Care and Use Committee.
 
Antibodies and Cytokines.
 
Unconjugated CD2, CD3, CD8,
CD4, B220, Ly6G/Gr1, Mac1, PE-conjugated Sca1, FITC-con-
jugated CD45.1, PE-conjugated CD45.2, Spectral red–conju-
gated Gr1, B220 and Mac1, biotinylated Thy1, cychrome-conju-
gated streptavidin, and FITC-conjugated goat anti–rat antibodies
(GARs) were purchased from Southern Biotechnology Associ-
ates, Inc. Unconjugated Ter119, allophycocyanin-conjugated
GARs, biotinylated anti–c-kit, and allophycocyanin-Cy7–conju-
gated streptavidin were purchased from BD Biosciences. Hoechst
33342 was purchased from Sigma-Aldrich. Recombinant mouse
flt3L, KL, TPO, TGF-
 
 
 
1, TGF-
 
 
 
2 and TGF-
 
 
 
3, polyclonal
pan-anti–TGF-
 
 
 
, and anti–TGF-RII antibodies were purchased
from R&D Systems. Supernatants obtained from BHK/HM-5,
BHK/MKL (both a gift from J. Matous, University of Washing-
ton, Seattle, WA), and WEHI 3B (a gift from S. Tsai, Mount Si-
nai School of Medicine, New York, NY) cells were used as a
source of GM-CSF, KL, and IL-3, respectively.
 
Isolation of Hematopoietic Progenitor and Stem Cells from Bone Mar-
row and Fetal Liver.
 
Low-density bone marrow cells were stained
with antibodies for lineage antigens, Sca1 and c-kit, and isolated by
cell sorting as described previously (9) to obtain lineage negative
(lin
 
 
 
) Sca1
 
  
 
kit
 
 
 
 cells (see Fig. 3 a for a representative example of
sort windows). Fetal liver was dissected from E14 fetuses. Single
cell suspensions were obtained by passing the cells through a nylon
mesh. Labeling of fetal liver cells was identical to labeling of bone
marrow cells, but the Mac-1 antibody (24) was omitted.
 
Culture of LSK Cells.
 
Sorted cells were cultured in triplicate
at 20–40 cells/well in flat-bottom 96-well plates in IMDM, 10%
FCS, 100 mg/ml penicillin/streptomycin, and 50 ng/ml flt3L,
TPO, and KL. 3 h after plating, the exact number of cells per
well was determined by visually counting the cells at a magnifica-
tion of 40. After 5 d of liquid culture at 37
 
 
 
C and 5% CO
 
2
 
, the
cells were counted again; in some experiments, 500 cells were
plated in methylcellulose cultures containing IMDM, IL-3 (10%
of WEHI 3B supernatant), GM-CSF (10% of BHK/HM-5 su-
pernatant), KL (10% of BHK/MKL supernatant), 2 U/ml eryth-
ropoietin, 10% FCS, 10 
 
 
 
g/ml anti–TGF-
 
 
 
, and 10
 
 
 
6
 
 M 
 
 
 
-thio-
glycerol. After 8 d of incubation at 37
 
 
 
C in a humidified
incubator with 5% CO
 
2
 
, the cultures were scored for colony for-
mation. Most secondary colonies were myeloid, with 20–40%
macroscopic colonies derived from high proliferative potential
cells. Colony-forming cell (CFC) output correlated with cellular
proliferation in the liquid culture phase in every experiment.
 
Cell Cycle Analysis of LSK Cells.
 
Bone marrow samples were
stained with lineage markers, followed by allophycocyanin-GAR,
Sca-1-PE, biotinylated anti–c-kit antibody, and finally with
streptavidin–allophycocyanin-Cy7. The cells were fixed over-
night in 1% paraformaldehyde and 0.2% Triton X-100. The fol-
lowing day, the cells were washed in PBS and labeled with
Hoechst 33342 at 4
 
 
 
C for 60 min. Analysis was performed on a
triple laser FACSVantage™ flow cytometer with DiVA software
(Becton Dickinson). Doublet exclusion using pulse-shape analysis
was done by plotting area versus height of the UV-excited
Hoechst fluorescence. A live gate on singlet LSK cells was used to
acquire up to 10
 
4
 
 cells.
 
Semi-quantitative RT-PCR.
 
Total RNA from purified LSK
cells was isolated using TRIzol reagent (GIBCO BRL) according
to the manufacturer’s instructions and treated with DNaseI. RNA
was reverse transcribed using Superscript II (GIBCO BRL), for
1 h at 42
 
 
 
C using oligo(dT) primers. PCR primers used were as
follows: 5
 
 
 
-TGAACCCTAAGGCCAACCGTG-3
 
 
 
 (nucleotide
[nt] 409-429) and 5
 
 
 
-GCTCATAGCTCTTCTCCAGGG-3
 
 
 
(nt  804-789) for actin; and 5
 
 
 
-ATGGCTTTGGATGCTGC-
CTA-3
 
  
 
(nt 2124-2143) and 5
 
 
 
-TTAGCTGCATTTACAAGA-
CTTGACCA-3
 
  
 
(nt 2436-2459) for TGF-
 
 
 
2, respectively.
 
Competitive Repopulation Assays.
 
2 
 
  
 
10
 
6
 
 bone marrow cells
or 10
 
5
 
 E14 fetal liver cells from 
 
Tgfb2
 
 
 
/
 
 
 
, 
 
Tgfb2
 
 
 
/
 
 
 
, or WT mice
(CD45.2
 
 
 
, competing cells), and equal numbers of heterozygous
B6.B6.SJL-
 
Ptprca
 
Pep3b/BoyJ
 
 mice (CD45.1
 
 
 
CD45.2
 
 
 
) or homozy-
gous B6.SJL-
 
Ptprca
 
Pep3b/BoyJ
 
 mice (CD45.1
 
 
 
; competitor cells)
were mixed and injected in lethally (950 cG) irradiated C57BL/
6.SJL-
 
Ptprca
 
Pep3b/BoyJ
 
 mice (CD45.1
 
 
 
). Peripheral blood cells were
analyzed for the expression of CD45.1, CD45.2, and lineage anti-
gens (Thy-1, Gr-1, and B220) 12–24 wk after transplantation.
Competitive serial transplantations were performed 12–24 wk af-
ter reconstitution by injecting 2 
 
  
 
10
 
6
 
 bone marrow cells from
primary recipients into lethally irradiated secondary C57BL/6
(CD45.1
 
 
 
) recipients, and from secondary recipients into lethally
irradiated tertiary C57BL/6 (CD45.1
 
 
 
) recipients. Three second-
ary or tertiary recipients were reconstituted with bone marrow
from one donor. All transplant recipients survived. After 3 mo,
the ratio between the competing cell populations cells was mea-
sured in the peripheral blood of the secondary or tertiary recipi-
ents. The data are presented as ratios between the two donor
populations a determined by the expression CD45 alleles.
Changes in reconstitution ratios between primary and secondary,
or between secondary and tertiary recipients were analyzed by
evaluating the difference in the logarithm of the reconstitution
ratios 
 
  
 
(log ratio) in the respective recipients. The rationale for 
Langer et al.
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using ratios is that the change in the reconstitution ratio between
primary and secondary recipients is a better measure of a shift in
reconstitution capacity upon serial transplantation than a change
in the percentage contribution of CD45.2
 
 
 
 cells between primary
and secondary recipients. This is because a change in the percent
CD45.2
 
 
 
 cells after serial transplantation from a 50% contribution
level in the primary recipient reflects a smaller change in the
function or the number of HSCs than the same change at higher
or lower contribution levels in the primary recipient (i.e., a 5%
change from 50 to 45% is a change in reconstitution ratio from 1
to 0.82, whereas a 5% change from 90 to 85% represents a much
larger change in reconstitution ratio from 9 to 5.6). A better mea-
sure is the ratio between the CD45.2
 
 
 
/CD45.1
 
 
 
CD45.2
 
 
 
 ratio
pre- (input, primary recipient) and postsecondary (output, sec-
ondary recipient) reconstitution. With ratiometric data, the dif-
ference between log CD45.2
 
 
 
/CD45.1
 
 
 
CD45.2
 
 
 
 ratios in pri-
mary and secondary recipients or in secondary and tertiary
recipients can be used. An advantage of log transformation is that
a ratio smaller than one will give a negative value, and negative
ratios will extend over the same numerical ranges as positive ones
(e.g., a ratio of 0.01 gives a log ratio of 
 
 
 
2, a ratio of 100 gives a
log ratio of 
 
 
 
2). Thus, data are presented as the difference be-
tween input log CD45.2
 
 
 
/CD45.1
 
 
 
CD45.2
 
 
 
 (i.e., the log ra-
tio in the first recipient) and the output log CD45.2
 
 
 
/CD45.1
 
 
 
CD45.2
 
 
 
 (i.e., the log ratio 3 mo after reconstitution of the serial
recipients), and will be referred to as 
 
  
 
(log ratio). Differences in
the efficiency of serial repopulation were assessed by comparing
the 
 
  
 
(log ratio) for recipients of WT or TGF-
 
 
 
2–deficient bone
marrow or fetal liver cells as competing cells.
 
Statistical Analysis. 
 
Student’s 
 
t
 
 test for unpaired samples was
used unless indicated otherwise.
 
Linkage Analysis in BXD RI Strains.
 
Linkage analysis was per-
formed in BXD RI strains. These are commercially available and
were generated by repeated inbreeding of F2 mice derived from
the inbred progenitor strains C57BL/6 and DBA/2. The genome
of RI strains is composed of a patchwork of homozygous chro-
mosome segments derived from either progenitor strain, with
each of the RI lines having a unique combination of “patches”
from the progenitors (25). Linkage analysis is performed by deter-
mining the relevant trait in each of the strains, which results
in a strain distribution pattern. The data are analyzed using
MapmanagerQTb29ppc software (26). This software statistically
analyzes the linkage of a given trait with previously typed poly-
morphic loci in the RI strains, which are inherited from either
parental strain. This allows assignment of a trait to a correspond-
ing map position, and the calculation of statistical significance ac-
cording to published criteria (27, 28). Mapping databases were
downloaded from www.nervenet.org/papers/bxn.html (29).
 
Results
The Dose Response of TGF- 2 on Primitive Hematopoietic
Progenitor Cells Is Biphasic and Subject to Mouse Strain–depen-
dent Variation. TGF- 1, - 2, or - 3 was added to liquid
cultures of LSK cells, a population highly enriched for he-
matopoietic stem and early progenitor cells (1, 2), supported
by KL, flt3L, and TPO. LSK cells from C57BL/6, DBA/2,
and BALB/c mice, three mouse strains that display geneti-
cally determined variation in the HSC compartment (5, 6),
were used for these experiments. In these cultures, the dose
response of TGF- 2 on the proliferation of LSK cells was
significantly less inhibitory than the dose responses of TGF-
 1 (Fig. 1 a) and TGF- 3 (not depicted). In addition, TGF-
 2 had a significant (P   0.05) net stimulatory effect on the
proliferation of LSK cells at the lowest concentration tested
(0.001 ng/ml) in the three mouse strains. These observations
indicate that, in vitro, TGF- 2 has a biphasic dose response
on the proliferation of LSK cells. Furthermore, the dose re-
sponse of TGF- 2 showed genetically determined variation
among the three mouse strains tested (Fig. 1 a). LSK cells
from BALB/c mice were significantly less responsive to the
inhibitory effect of TGF- 2 at higher concentrations, and
more responsive to the stimulatory effect of TGF- 2 at low
concentrations than LSK cells from DBA/2 and C57BL/6
mice. In contrast to the dose response of TGF- 2, the dose
responses of TGF- 1 (Fig. 1 a) and TGF- 3 (not depicted)
were similar in these three mouse strains.
To determine whether the stimulatory effect of low con-
centrations of TGF- 2 was direct, we deposited single LSK
cells from C57BL/6 mice in individual wells of 96-well
plates in the presence of KL, flt3L, and TPO with and
Figure 1. Effect of TGF- 2 in vitro. (a) Dose response of TGF- 1
and TGF- 2 on proliferation in 5-d cultures of LSK cells from the
mouse strains listed (top), supported by KL, flt3L, and TPO (mean  
SEM; n   3–13; *, significantly different DBA/2 and C57BL/6). (b) Effect of
0.001 ng/ml TGF- 2 on cloning efficiency (left) and on average clone
size (right) of single cell–sorted LSK cells from C57BL/6 mice (mean  
SEM; n   5). (c) Representative example of the colony-size distribution
after 5 d of single cell culture supported by KL, flt3L, and TPO of fetal
liver LSK cells in the presence of TGF- 2 at 0.001 ng/ml. (d) Effect of
neutralizing anti–TGF-RII antibodies on the effect of 0.001 ng/ml TGF- 2
on the proliferation of LSK cells from C57BL/6 (mean   SEM; n   5).
(e) Expression of TGF- 2 mRNA in purified LSK cells, lineage positive
cells from fetal liver, and adult bone marrow as detected by RT PCR.
(f) Effect of an affinity-purified polyclonal anti–TGF- 2 antibody on the
proliferation of LSK cells supported by KL, flt3L, and TPO after preincu-
bation of the antibody with recombinant TGF- 2 at the depicted con-
centrations (bottom, mean   SEM; n   3; *, significantly different from
control without TGF- 2 or anti–TGF- 2; P   0.04).TGF- 2 Regulation of HSC 8
without 0.001 ng/ml TGF- 2. The addition of TGF- 2 at
this concentration did not affect the cloning efficiency of
these progenitors, which was  70% (Fig. 1 b). However, it
did increase the average clone size by  1.9-fold (Fig. 1 b,
P   0.013) after 5 d of culture. A representative example
using fetal liver–derived LSK cells is shown in Fig. 1 c.
These data demonstrate that TGF- 2 directly enhances the
proliferative potential of LSK cells responsive to early act-
ing cytokines, rather than initiating proliferation in nonre-
sponsive cells.
TGF-  binds to the type II TGF receptor (TGF-RII),
which associates with and phosphorylates the TGF-RI,
thereby triggering a signaling cascade mediated by Smad
proteins (20, 21). The fact that low concentrations of TGF-
 2 are stimulatory, in contrast to the potent inhibitory ef-
fects of other TGF-  isoforms (14–19, 22) on the prolifer-
ation of primitive hematopoietic progenitor cells, might
suggest that this effect is mediated by a different receptor.
To address this question, we examined the effects of TGF-
 2 in the presence of neutralizing antibodies to the TGF-
RII. These antibodies blocked the stimulatory effect of
TGF- 2 (at 0.001 ng/ml) on the proliferation of LSK cells
(Fig. 1 d), suggesting involvement of the canonical TGF-
RII in the observed stimulatory response.
TGF- 1 is produced in primitive progenitor cells, and
inhibition of TGF- 1 activity enhances the proliferative
capacity of these cells in vitro (15). Therefore, we tested
whether TGF- 2 is also expressed in LSK cells. RT PCR
analysis showed that TGF- 2 mRNA is expressed in puri-
fied fetal liver and bone marrow–derived LSK cells (Fig. 1
e). Expression of TGF- 3 was not detected (unpublished
data). To investigate whether endogenous TGF- 2 affects
the proliferative capacity of LSK cells, we tested the effect
of anti–TGF- 2 antibodies. Affinity-purified anti–TGF- 2
antibodies significantly inhibited proliferation of LSK cells
supported by the early acting cytokines flt3L, KL, and TPO
by  50% (Fig. 1 f, P   0.04). Preincubation of the anti-
body with recombinant TGF- 2 alleviated the inhibitory
effect of these antibodies (Fig. 1 f), indicating that this ef-
fect was not due to toxicity. In contrast, addition of anti–
TGF- 1 antibodies enhanced the proliferation of LSK cells
two- to threefold (unpublished data), a finding consistent
with previously published data (15).
Linkage Analysis in BXD RI Strains. To further investi-
gate mouse strain–dependent variation in the dose response
of TGF- 2, we performed linkage analysis using BXD RI
strains. Although the TGF- 2 dose response in LSK cells
from C57BL/6 and DBA/2 mice (the progenitors of the
BXD RI set) was very similar, linkage analysis was at-
tempted using these strains because a relatively large num-
ber are readily available in this set. If a trait is multigenic,
phenotypic variation can be more pronounced among RI
strains than between their progenitor strains because the
balance between positive-acting and negative-acting alleles
present in the progenitor strains may be completely unbal-
anced in some of the RI strains (25). This may allow quan-
titative trait locus (QTL) identification, even when pheno-
typic variation between the progenitor strains is not
significant. The effect of TGF- 2 at 0.1 ng/ml on the pro-
liferation of LSK cells from 30 BXD RI strains was mea-
sured because this concentration revealed the most pro-
nounced difference in the TGF- 2 dose response between
the inbred strains (Fig. 1 a). The individual BXD strains
showed wide variation in this assay (Fig. 2 a), indicating
that the responsiveness to TGF- 2 is indeed a multigenic
trait. One QTL contributing to the effect of TGF- 2 was
identified on chromosome 4 between 67 (D4Mit158) and
79 (D4Mit33) cM (maximum likelihood ratio statistic 13.7;
P   0.00021). The level of significance was suggestive ac-
cording to permutation analysis (27, 28). Although sugges-
tive QTL require confirmation (28), the location of this
QTL was compelling because this interval overlaps with
the interval containing a previously identified QTL con-
tributing to genetic variation in the pool size of lin Sca1  
and of LSK cells in vivo (Fig. 2 b; reference 9). Further-
more, a significant correlation was found between the ef-
fect of TGF- 2 and the number of lin Sca1   cells in
BXD RI strains (Fig. 2 c). One interpretation of these find-
ings is that TGF- 2 signaling regulates the size of the he-
matopoietic stem and progenitor cell compartment as de-
fined by phenotype in vivo.
Studies in Tgfb2 /  and Tgfb2 /  Fetal Liver. The QTL
analysis suggested that TGF- 2 may be a regulator of the
hematopoietic stem and progenitor cell compartment rele-
vant in vivo. To test this hypothesis, we investigated the
hematopoietic phenotype of TGF- 2–deficient mice. As
Tgfb2 /  mice die at birth from multiple malformations
(30), we examined the hematopoietic phenotype of fetal
livers from Tgfb2 /  and Tgfb2 /  mice. To allow trans-
Figure 2. Linkage analysis in BXD RI strains. (a) Strain distribution
pattern of the effect of 0.1 ng/ml TGF- 2 on the KL, flt3L, and TPO-
supported proliferation of LSK cells in BXD mice (mean   SEM; n   2–4).
(b) Pattern of likelihood ratio statistic (y axis) values along chromosome 4
for the absolute number of lin Sca1   cells (reference 9) and their respon-
siveness to TGF- 2. The y axis scale is relative to normalize the size of
both peaks (the maximum likelihood ratio statistic value is 15.9 for the
number of lin Sca1   cells, and 13.7 of the effect of TGF- 2). (c) Correla-
tion between the effect of TGF- 2 on the proliferation of LSK cells (a)
and the frequency of lin Sca1   cells (reference 9).Langer et al. 9
plantation experiments, Tgfb2 /  mice were backcrossed
onto the C57BL/6 background for at least six generations.
The frequency of LSK cells and the proliferative capacity
of these cells in vitro did not differ in mutant and WT fetal
livers (unpublished data). To assess the repopulation poten-
tial of mutant HSCs, 105 fetal liver cells from Tgfb2 / ,
Tgfb2 / , or WT fetuses (CD45.2 ) were transplanted to-
gether with 2    105 bone marrow cells from congenic
C57BL/6.SJL-PtprcaPep3b/BoyJ (CD45.1 ) mice into CD45.1 
recipients (31). As expected (32), fetal liver cells dis-
played a significantly higher repopulation potential than
adult bone marrow cells (Fig. 3 a, mean fetal/adult reconsti-
tution ratio  1 after 12–24 wk) (21). There appeared to be
no significant difference in the repopulation capacity of
Tgfb2 / , Tgfb2 / , and WT fetal liver cells (Fig. 3 a). To-
gether, these data suggest that TGF- 2 plays no role in fetal
hematopoiesis. To further evaluate the repopulation capac-
ity of these cells, we performed serial transplantations by in-
jecting 2   106 bone marrow cells from primary recipients
into secondary C57BL/6 (CD45.1 ) recipients 12–24 wk
after reconstitution. After 3 mo, the ratio of CD45.2 /
CD45.1  cells was measured in the peripheral blood of the
secondary recipients. We used the difference between log
CD45.2 /CD45.1  ratios in primary and secondary recipi-
ents (  [log ratio]; Materials and Methods) for statistical
analysis (Fig. 3 b). Although WT fetal liver cells maintained
their repopulating capacity in the secondary recipients,
Tgfb2 /  and Tgfb2 /  fetal liver cells showed a marked re-
duction in this capacity after transplantation. The lower sec-
ondary repopulating capacity in Tgfb2    and Tgfb2    mice
affected all lineages (unpublished data). The difference in se-
rial reconstitution capacity between Tgfb2 /  or Tgfb2 / ,
Figure 3. Hematopoietic phenotype of Tgfb2 /  and Tgfb2 /  E14 fetal
mice. (a) Competitive repopulation of 105 Tgfb2 / , Tgfb2 / , and WT
(wt) fetal liver cells against 2   105 C57BL/6 bone marrow cells analyzed
12–16 wk after transplantation. Data are expressed as ratio between fetal
liver–derived (CD45.2 ) and C57BL/6 adult bone marrow–derived
(CD45.1 ) cells in the peripheral blood. (b) Log ratio CD45.2 /CD45.1 
in individual primary and secondary recipients in serial repopulation
experiments from primary donors reconstituted with fetal liver–derived
cells (Tgfb2 / , Tgfb2 / , or WT) as competing cells. (c) Average   [log
ratio    log(CD45.2/CD45.1) in primary recipients   log(CD45.2/
CD45.1) in secondary recipients] for WT, Tgfb2 / , and Tgfb2 /  fetal liver
cells upon serial transplantation (mean   SEM; n   9 for each genotype).
Figure 4. Hematopoietic phenotype of adult Tgfb2 /  mice. (a) Rep-
resentative example of flow cytometric analysis of the frequency of
lin Sca1   and LSK cells in bone marrow of Tgfb2 /  mice and WT (wt)
littermates. Bone marrow was pooled from three mice for each genotype. 106
events were recorded. (b) Proliferation and CFC output in pre-CFC assays of
LSK cells from Tgfb2 /  mice or WT littermates. In each experiment,
bone marrow was pooled from three mice for each genotype. (c) Com-
petitive repopulation of 2   106 WT or Tgfb2 /  bone marrow cells with
2   106 C57BL/6-derived bone marrow cells in C57BL/6 recipients.
Data are expressed as ratio for each individual recipient between
WT or Tgfb2 / -derived (CD45.2) and C57BL/6 competitor–derived
(CD45.1 CD45.2 ) reconstitution at 12 wk. (d) Log ratio CD45.2 /
CD45.1 CD45.2  in individual primary, secondary, and tertiary recipients in
serial repopulation experiments from primary donors reconstituted with
Tgfb2 /  or WT bone marrow cells as competing cells. (e) Average   (log
ratio) for WT and Tgfb2 /  bone marrow cells upon serial transplantation
(mean   SEM; n   9 for each genotype). (f) Fraction of LSK cells and of
cells falling outside the LSK window (non-LSK) in S/G2/M phase of the
cell cycle in Tgfb2 /  mice and WT littermates (n   4 experiments using
mice from different litters). (g) Log (CD45.2 /CD45.1 CD45.2 ) in
individual recipients in serial competitive repopulation experiments from
primary donors reconstituted with adult bone marrow–derived cells
(Tgfb2 /  or WT; CD45.2 ) as competing cells and with
CD45.1 CD45.2  C57BL/6-derived bone marrow cells as competitor
cells. In contrast to the primary recipients shown in Fig. 4 d, the primary
recipients in this experiment were treated with 5-FU 12 wk after primary
reconstitution and 6 wk before secondary transplantation. (h) Average  
(log ratio) for WT and Tgfb2 /  bone marrow cells upon serial transplan-
tation after treatment of primary recipients with 5-FU (mean   SEM;
n   3 for WT; n   6 for Tgfb2   ).TGF- 2 Regulation of HSC 10
and WT fetal liver HSCs was approximately fourfold (Fig. 3
c). The serial reconstitution capacity of Tgfb2 /  and
Tgfb2 /  fetal liver cells was similar (Fig. 3 c), indicating
dominance of Tgfb2 for this particular biological effect.
These findings indicate that TGF- 2 is important for main-
taining the serial repopulation capacity of fetal liver HSCs
and suggest a positive regulatory role of TGF- 2 in vivo.
Given that Tgfb2    and Tgfb2    HSCs were exposed to a
WT microenvironment in the primary recipients, the
observed deficiency in secondary repopulation potential
strongly suggests that TGF- 2 may act in a cell autonomous
fashion. The finding that TGF- 2 mRNA is expressed in
purified LSK cells (Fig. 1 e) supports this contention.
TGF- 2 Is a Positive Regulator of Adult Hematopoiesis.
Because Tgfb2 /  mice are viable, and because Tgfb2    fe-
tal liver HSCs showed a defect relative to WT cells, we
were interested in determining whether adult Tgfb2   
HSC were also defective. Peripheral white and red cell
counts were similar in Tgfb2 /  mice and in their WT lit-
termates (unpublished data). However, bone marrow cellu-
larity in Tgfb2 /  mice was slightly, but significantly lower
than in WT littermates (2.012   0.61   107 vs. 1.86  
0.60   107 cells/femur, P   0.03 by paired Student’s t test,
using bone marrow pooled from at least three mice in each
experiment; unpublished data). In contrast to end-stage
cells, the numbers of early progenitor/stem cells were re-
duced in heterozygous animals. The fraction of lin Sca1  
cells and of LSK cells were 34   6% (P   0.03) and 41  
30% (P   0.01) lower in Tgfb2    mice than in WT mice,
respectively (paired Student’s t test, n   4, using bone mar-
row pooled from at least three mice in each experiment;
Fig. 4 depicts a representative example). These findings
suggest that TGF- 2 positively regulates the number of
adult LSK cells in vivo, and corroborate the overlapping
intervals for QTL contributing to genetic variation in the
frequency of LSK cells on one hand, and responsiveness of
LSK cells to TGF- 2 on the other hand. In culture assays,
proliferation and CFC generation in response to KL, flt3L,
and TPO of purified LSK cells from Tgfb2 /  mice were
significantly lower than from WT littermates (Fig. 4 b),
again supporting a positive regulatory role for TGF- 2 in
adult early hematopoietic progenitors.
To analyze the reconstitution capacity of adult Tgfb2   
HSCs, we transplanted lethally irradiated C57BL/6 recipi-
ents (CD45.1) with 2   106 bone marrow cells from either
Tgfb2 /  mice or from WT littermates (CD45.2 ), and
equal numbers of C57BL/6-derived bone marrow cells
(CD45.1 CD45.2 ). These experiments revealed a defect
in adult Tgfb2 /  HSCs in primary recipients. The ratio of
Tgfb2    to competitor cells in the peripheral blood of re-
cipients mice was 1.32   0.11. This was significantly lower
than the ratio of WT to competitor cells (Fig. 4 c, 1.77  
0.14; n   10). We found the same ratio in all lineages (un-
published data). As observed in fetal liver, the difference in
the repopulation capacity between WT and Tgfb2 / 
HSCs was more pronounced after transplantation into sec-
ondary recipients after 12 wk (Fig. 4 d). The mean differ-
ence in   (log ratio) between WT and Tgfb2 /  HSC was
0.476, corresponding to a threefold loss in repopulating ca-
pacity of Tgfb2    HSCs upon transplantation into second-
ary hosts (Fig. 4 e). After transplantation into tertiary recip-
ients, the mean difference in   (log ratio) between WT and
Tgfb2 /  HSCs increased further to 1.024, representing a
10-fold difference in repopulating capacity (Fig. 4, d and
e). Regardless of the expression level of TGF- 2, bone
marrow cells from both the WT and the Tgfb2 /  back-
crossed mice outcompeted bone marrow cells from
C57BL/6 mice in primary recipients (Fig. 4 c), whereas in
secondary and tertiary recipients, the competitive advan-
tage of the bone marrow of WT backcrossed mice in-
creased even further (Fig. 4 d). A relative defect in the
competitive repopulation capacity of CD45.1  compared
with CD45.2  bone marrow cells has been observed by
other investigators as well (see Fig. 5 in reference 33). Al-
though the underlying reason for this is not clear, it is pos-
sible that the allelic difference at the Cd45 locus could play
a role, given the role of CD45 in cytokine signal transduc-
tion as a tyrosine phosphatase (34). Irrespective of this phe-
nomenon, the repopulation studies clearly demonstrate that
Tgfb2 /  bone marrow has a significantly lower serial re-
constitution capacity than the bone marrow from WT lit-
termates. As in the experiments using fetal liver cells, the
loss of repopulation capacity of adult Tgfb2 /  HSCs upon
serial transplantation may suggest that TGF- 2 acts in a cell
autonomous fashion.
HSCs have been shown to cycle slowly. In C57BL/6
mice,  8% of HSCs enter cycle per day (35). Furthermore,
after reconstitution of a lethally irradiated recipient, HSCs
display enhanced cycling activity for at least 4 mo (36).
HSCs in cell cycle may engraft less efficiently (37). There-
fore, it is possible that the decreased serial reconstitution
capacity of Tgfb2 /  HSCs compared with WT HSCs is
due to enhanced cycling of the former. This would imply
that TGF- 2 is, in fact, a negative regulator of HSCs cy-
cling in vivo. To investigate cycling activity within the
HSC compartment of Tgfb2 /  mice, we compared the
cell cycle of Tgfb2 /  and WT LSK cells by four-color
flow cytometry. Fixed bone marrow samples from Tgfb2 / 
mice and from WT littermates were stained with the
DNA-binding dye Hoechst 33342 and by antibodies
against lineage markers, Sca-1, and c-kit. As shown in Fig.
4 f, significantly fewer LSK cells were in S/G2/M phase of
the cell cycle in Tgfb2 /  mice, as determined by Hoechst
33342 staining. The fraction of cells in the S/G2/M phase
of the cells cycle was similar in the total bone marrow pop-
ulation of Tgfb2 /  mice and WT littermates, indicating
that the positive regulatory effect of TGF- 2 is specific for
the LSK compartment. A difference in the cell cycle activ-
ity of WT and Tgfb2 /  HSCs would confer differential
sensitivity of these HSCs to drugs that selectively target cy-
cling cells, such as 5-fluorouracil (5-FU) (38). Therefore,
primary recipients of mixtures of bone marrow from
CD45.1 CD45.2  C57BL/6 mice, and CD45.2  WT or
Tgfb2 /  mice were injected with 150 mg/kg 5-FU 3 moLanger et al. 11
after reconstitution. 6 wk later, 2   106 bone marrow cells
of these mice were injected into lethally irradiated second-
ary CD45.1  recipients, which were analyzed 3 mo later.
After injection of primary recipients with 5-FU, Tgfb2 / 
HSCs gained repopulating capacity, whereas WT HSCs
lost repopulating capacity compared with C57BL/6-
derived competitor cells in secondary recipients (Fig. 4, g
and h). This repopulating potential was opposite of that ob-
served with bone marrow from untreated mice (Fig. 4, d
and e), indicating that 5-FU differentially affects WT and
Tgfb2 /  HSCs. Because the Tgfb2 /  HSCs are less sensi-
tive to the effects of 5-FU, these data are consistent with
the interpretation than Tgfb2 /  HSC cycle less frequently
than WT HSCs. Together, our data demonstrate that
TGF- 2 enhances the cell cycle activity of the LSK com-
partment, including repopulating HSCs.
Discussion
The key observations of this work are, first, that TGF-
 2 is a positive regulator of HSC function in vivo; second,
that TGF- 2 may act in a cell autonomous fashion; and
third, that the dose response of TGF- 2 on LSK cells is
subject to quantitative genetic variation.
Although the TGF-  system is believed to play a role in
the maintenance of HSCs in quiescence (15), our findings
show that at least one TGF-  isoform, TGF- 2, is a posi-
tive regulator of HSCs in vivo and in vitro. In vitro, a di-
rect stimulatory effect of TGF- 2 on the proliferation of
LSK cells could be detected only at low concentrations,
whereas at higher concentrations, TGF- 2 was a signifi-
cantly weaker inhibitor of proliferation than TGF- 1 and
TGF- 2. The phenotype of TGF- 2–deficient mice sug-
gests that it is the stimulatory effect of TGF- 2, detected in
vitro at low concentrations, that is relevant in vivo. The
three known TGF-  isoforms in mice and humans have
clearly distinct roles in vivo, as evidenced by the wide vari-
ation in the phenotypes of mice with a homozygous dele-
tion of the genes encoding the individual TGF-  isoforms.
Because all TGF-  isoforms activate the same Smad-medi-
ated signaling pathway, these data are likely explained, at
least in part, by their different expression patterns (20, 21).
However, a role for intrinsically different effects of TGF- 
isoforms on specific cell types cannot be excluded. For ex-
ample, in vivo and in embryonic skin organ cultures in
vitro, hair follicle morphogenesis is enhanced by TGF- 2
and inhibited by TGF- 1 (39). The data presented here in-
dicate that also in the regulation of renewal and differentia-
tion of HSCs, TGF- 1, and TGF- 2 play different, and
even opposing roles. A molecular explanation for these data
could lie in the differences between TGF- 2 on one hand
and TGF- 1 and - 3 on the other hand with respect to re-
ceptor binding. The TGF-RII (40), as well as accessory re-
ceptors including endoglin (41), which is expressed on
repopulating HSCs (42), TGF-RIII (43), and some less
well-characterized proteins (44, 45) display differential bind-
ing affinities for TGF- 1 or - 3 compared with TGF- 2.
Therefore, these proteins may be involved in the divergent
hematopoietic effects of TGF- 2 compared with TGF- 1
and TGF- 3.
Despite a defect in the hematopoietic stem and progeni-
tor cell compartment, and even a small decrease in bone
marrow cellularity, peripheral blood counts were normal in
Tgfb2    mice. These observations indicate that different
and independent homeostatic mechanisms operate in the
regulation of the early and late stages of hematopoiesis. The
defect in serial repopulation capacity of TGF- 2–deficient
HSCs together with their lower sensitivity to the toxicity
of 5-FU indicates that TGF- 2 acts on the most primitive
HSCs. However, TGF- 2 induced a general increase in
the clone size of growing LSK cells. LSK cells are still a
functionally heterogeneous population, and only a minor-
ity of these cells are repopulating HSCs (1, 2). Further-
more, the proliferation of LSK cells in vitro is mainly dif-
ferentiative. Therefore, our data indicate that TGF- 2
positively regulates a primitive progenitor cell population
that includes, but is not limited to, the renewing HSCs.
The defect in the serial repopulation capacity of TGF-
 2–deficient HSCs suggests that TGF- 2 positively regu-
lates HSCs in a cell autonomous, and likely autocrine, fash-
ion in vivo. Although this contention is supported by our
in vitro data showing a lower proliferative capacity of
Tgfb2    LSK cells and an inhibitory effect of anti–TGF- 2
antibodies on the proliferation of LSK cells, it cannot be
entirely excluded that this defect is caused by the disappear-
ance of a critical cellular element required for HSC prolif-
eration and engraftment. However, the fact that in the se-
rial transplantation experiments, WT C57BL/6 bone
marrow cells were always cotransplanted makes this possi-
bility unlikely. Autocrine regulation of HSCs has been
demonstrated recently for vascular endothelial growth fac-
tor (46), and has been proposed for several other cytokines
(47). An autocrine negative regulatory role of TGF- 1 has
been suggested based previously on in vitro data, although
its significance in vivo is unknown thus far (15). Thus, the
findings reported here may support the emerging concept
that cell-autonomous, intrinsic mechanisms mediated by
soluble factors participate in the regulation of HSCs.
The observation that TGF- 2 plays no role in fetal he-
matopoiesis in vivo is consistent with the finding that
TGF- 2 regulates the responsiveness of LSK cells to KL,
flt3L, and TPO. These cytokines and their respective re-
ceptors (c-kit, flt3, and c-mpl) are most critical in postnatal
hematopoiesis (12, 13), although KL plays a role in late-
stage fetal hematopoiesis as well (48, 49). However, in
TGF- 2–deficient fetal HSCs, a defect appeared upon se-
rial transplantation, whereas in adult Tgfb2    HSCs, the
existing repopulation defect increased upon serial trans-
plantation. Fetal and adult HSCs differ in their proliferative
history (50), whereas repopulation of a lethally irradiated
recipient represents a significant proliferative stress for
HSCs (36). Therefore, these findings suggest that TGF- 2
is mainly important for the function of long-term repopu-
lating HSCs that have undergone replicative stress. An al-TGF- 2 Regulation of HSC 12
ternative explanation for these data is that because the stim-
ulatory effect of TGF- 2 on LSK cells is subtle in vitro, a
deficiency in TGF- 2 only gives rise to detectable pheno-
type after multiple renewal divisions (i.e., in adult HSCs or
after serial transplantation). It is anticipated that the pheno-
type of Tgfb2    mice will increase with aging. However, it
has been proposed by several authors that a decrease in re-
constitution capacity upon serial transplantation is not nec-
essarily or not only due to replicative senescence (51, 52).
Our data suggest that, because WT HSCs are more effi-
cient at serial reconstitution that TGF- 2–deficient HSCs,
TGF- 2 may be implicated in this phenomenon.
An alternative explanation for the apparent reconstitut-
ing defect of TGF- 2–deficient HSCs may be that TGF-
 2–deficient mature cells have a shorter life span, so that
they will contribute less to the peripheral blood, without a
real defect in stem cell function. However, our data argue
against this contention. First, the defects in reconstitution
were found in all lineages to a similar extent. Given the
vastly different turnover rates of different types of blood
cells, it would be difficult to explain these data by a gener-
alized effect of TGF- 2 on the life span of mature cells.
Second, our in vivo 5-FU suicide data suggest that Tgfb2   
HSCs cycle more slowly than WT HSCs, indicative of a
stem cell phenotype. The comparative cell cycle analysis of
LSK cells from Tgfb2    mice and from WT littermates in
vivo again supports the idea that TGF- 2 is a specific posi-
tive regulator of the cycling activity in the stem cell com-
partment. Finally, the serial transplantation data strongly
support the contention that the effect of TGF- 2 is situ-
ated at the level of the stem cell compartment, and not at
the level of survival of mature cells. Mature cells do not
contribute to the peripheral blood 3 mo after transplanta-
tion. An increasing defect in repopulation capacity after
each round of serial transplantation can only be due to a
defect in the HSCs because that is the only cell that is re-
sponsible for the serial reconstitution (1, 2). If only life
spans of mature cells were affected, we would expect to
see a similar small defect after each round of transplanta-
tion.
Although TGF- 2 responsiveness is a multigenic trait,
only one suggestive QTL was identified in our paper. The
lower frequency of lin-Sca1   and of LSK cells in Tgfb2   
mice corroborates the overlapping QTL on chromosome 4
for the dose response to TGF- 2 and for the number and
frequency of lin Sca1   and of LSK cells in BXD RI
strains. Because Tgfb2    mice show a defect in the serial
reconstitution capacity of HSCs, it is likely that genetically
determined variation in the responsiveness to TGF- 2 also
affects the function of HSCs in vivo. However, direct link-
age analysis for the serial reconstitution capacity of HSC in
BXD RI strains is impossible because of their immunologi-
cal heterogeneity. Given the potential role of TGF- 2 in
maintaining the function of HSCs that have undergone
replicative stress, it will be of interest to determine whether
TGF- 2 also plays a role in the significant genetic variation
in the age-related decline in HSC function in inbred mice
(3, 4, 11, 53), which has been shown to be caused by cell
intrinsic mechanisms (3, 4).
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